IPG Photonics Corporation entered into a Share Purchase Agreement to acquire 100% of Lumibird Medical from Lumibird S.A. for €300 million in cash on a debt-free basis, subject to customary adjustments. The transaction includes contingent earn-out consideration of up to €50 million based on 2026 and 2027 performance metrics. IPG intends to fund the acquisition using existing cash reserves and has secured warranty and indemnity insurance. Closing is expected in the fourth quarter of 2026, pending regulatory approvals from the French Minister of the Economy and the Autorité des marchés financiers. IPG Photonics Corporation operates in the photonics industry, manufacturing fiber lasers and laser-based systems for industrial, medical, and defense applications.

IPG Photonics Corporation reported financial results for the quarter ended June 30, 2026. Second-quarter revenue increased 11% year-over-year to $278.6 million, driven by a 16% rise in Industrial Solutions sales. GAAP net income decreased 21% to $5.2 million, or $0.12 per diluted share, compared to $6.6 million and $0.16 per share in the prior year period. Adjusted EBITDA rose 54% to $48.5 million, and adjusted EPS increased 93% to $0.58. The company provided third-quarter guidance of $265 million to $295 million in revenue and adjusted EPS between $0.30 and $0.60. IPG Photonics Corporation operates in the laser technology industry, manufacturing fiber lasers for industrial, medical, and defense applications.